12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

Rosinol L, Perez-Simon JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, Gonzalez JD, Diaz-Mediavilla J,
hernadez B, Garcia-Frade J, Carrera D, Leon A, Hernandez M, Abellan PF, Bergua JM, Miguel JS, Bladé J. A
prosoective PETHEMA study of tandem autologous transplantation versus autograft followed by reduce-intensity
conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2009; 112: 3591-3.
Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, Agura ED, McSweeney PA, Pulsipher MA, Hari P,
Maziarz RT, Chauncey TR, Appelbaum FR, Sorror ML, Bensinger W, Sandmaier BM, Storb RF, Maloney DG.
Long-term putcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and
nonmyeloablative allografting. Blood 2009; 113: 3383-91.
Segeren CM, Sonneveld P, Van der Holt B et al. Overall and event-free survival are not improved by the use of
myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple
myeloma: a prospective randomized phase 3 study. Blood 2003; 101: 2144-51.
104